Established in 2015 by Swiss investors, Swyssi is thriving as a fast-growing market entry and brand building curator in prescription pharmaceuticals across the world.
Swyssi specializes in developing and manufacturing complex generic drugs and simultaneously, often in close conjunction, extending the life-cycle of divested mature prescription pharmaceuticals – chiefly in the cardiovascular, diabetes, CNS, respiratory field and more. Swyssi adheres to the highest standards of quality, safety and efficacy in the development and manufacturing of healthcare products.
Swyssi supports and applies science and invests global resources in advanced technologies as well as in bouncing back sales of established brands. Our value proposition is through research and scientific knowledge to bring new and established mass therapies to patients, extending and significantly improving their lives at affordable prices.
Our Business Model
We believe for many years in and now profoundly commend the recent FDA Commissioner Scott Gottlieb’s conclusion that “when companies are discouraged from pursuing generics, the lack of completion prevents patients from getting access to affordable medications.”
The competitive harmony of innovative pharmaceuticals and complex generic drug applications serves our mission: Aging population needs ageless medications!
Ideally, getting the off-patent pharmaceuticals ahead of maturing is the ultimate goal of our expertise. This is not the attempted regulatory ‘evergreening’ practiced by some conglomerates immediately after patent expiration in order to fend off the generic competition for couple of more years. Product life-cycle extension is based on finding value in mature products for further single or more often combined prescription in a growing number of diagnoses.
Management
Takvor Boghossian, MBA
Chief Executive Officer
Takvor is an experienced professional in the pharmaceutical business with more than 25 years of expertise in leading and managing various projects. He is at the forefront of the successful development of the company and is shaping the future strategy and target formulations. Educational background: Master’s degree in Health Care Management – Medical University Sofia, Bulgaria, Master of Business Administration – New Bulgarian University Sofia, Bulgaria; Melkonian Educational Institute – Nicosia, Cyprus. Takvor has accomplished numerous senior management qualifications and expertise upgrades, and accumulated vast experience in projects with the leading European and the US institutions and corporations in Switzerland, France, Russia, the USA, Austria, Germany, the Kingdom of Saudi Arabia, etc.